Calithera Biosciences

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Calithera Biosciences was founded in 2009 by award-winning scientist and entrepreneur, Dr. Susan Molineaux, who also serves as the company’s CEO. Calithera has been backed by leading venture capital firms, and has performed multiple successful financings. The company is headquartered in South San Francisco, CA.

At Calithera, our mission is to discover, develop and commercialize novel small molecule therapies that address unmet needs in cancer.

We are focused on delivering life-transforming treatments for cancer patients that focus on controlling and modifying tumor metabolism and immune-oncology pathways.

Read More:

CFO roles and responsibilities

CEO roles and responsibilities

CTO roles and responsibilities

ddb worldwide media

vrr parking

Calithera has been recognized with several awards including 2016 California Life Sciences Excellence Award: Best Biotech Startup in South San Francisco, 2016 ACG 2016 Disruptive Technology Transformative Technology Award, and 2016 The Deal Pipeline TechDeals Trailblazer Award. In 2015 Calithera was recognized with the 2015 East Bay Innovation Award in the Best Biotech/Life Science Technologies.